Open Orphan Share Discussion Threads

[sh0wmethemoney] 08/1/2021 17:28

Reference post 1036:-

I know we are close with the Pneumococcal CS, does any one know if anyone else does them currently? Could be additional work stream here.

[sh0wmethemoney] 08/1/2021 17:15

Ended last Thursday with that 150k buy at 25.82 and ended this week with a sale at 25.82. So with the midweek news that’s good going by me.

[supernumerary] 08/1/2021 17:14

Not directly relevant but I thought the comment about vaccine work being here to stay was reassuring :)



Buoyed by renewed clamor for infectious disease R&D, Affinivax nabs huge $226M funding round
by Ben Adams | Jan 8, 2021 8:35am

After getting off a meaty $120 million round in April, the height of the first wave of COVID-19 infections in the West, Affinivax is a clear indicator that infectious disease and vaccine work is here to stay.

Nearly doubling that already impressive B round, the Cambridge, Massachusetts-based biotech has nabbed $226 million, with goals of unseating Pfizer’s Prevnar franchise as well as pushing a set of vaccines for hospital-associated infections into the clinic.

Its lead program works as a Prevnar 13 challenger that covers 24 strains of pneumococcus and is fully financed by a partnership with Astellas, as the pair hopes to beat out Pfizer’s big-selling vaccine and its expanded 20-strain effort.

“We’ll take that $120 million and fund additional vaccines—we’re not stopping at 24, even though 24 already beats Prevnar 20,” Affinivax CEO Steve Brugger told Fierce Biotech back in April.

Affinivax’s pipeline is based on the multiple antigen-presenting system (MAPS), which allows the protein itself to induce an immune response, too. The new cash haul will be put toward its MAPS platform.

That $226 million, which in itself would have been an impressive sum for an already on-fire biotech IPO market, was co-led by new investors Rock Springs Capital and Foresite Capital.

Additional new investors included T. Rowe Price, Wellington Management, funds and accounts managed by Blackrock, Cormorant Asset Management, Perceptive Advisors, EcoR1 Capital, Surveyor Capital (a Citadel company) and Logos Capital. They were joined by existing investors Viking Global Investors, Bain Capital Life Sciences and Ziff Capital Healthcare Ventures.

Founded in 2014 with tech out of Boston Children’s Hospital, the company picked up its seed and series A financing from the Bill & Melinda Gates Foundation. In 2017, it bagged another $10 million upfront when it licensed its lead program to Astellas, which will develop and commercialize the vaccine.

As Affinivax plugs away at its in-house pneumococcus efforts as well as a suite of programs targeting multiple hospital-associated infections, it is also doing early-stage work in cancer and exploring the use of its technology against viruses, including the new coronavirus behind the COVID-19 pandemic.

[jeanesy] 08/1/2021 15:46

this is a great company Bobsworth with an amazing Leader who keeps on delivering. We are in the right space at the right time. Just sit on your hands and buy on the dips if you can until the time that reality returns to the market !!

[bobsworth] 08/1/2021 12:27

Thanks Guys for your chin up posts.
You are all bang right.
Patience & News flow will finally unlock this share again.
All frustrating I know but no worries as I am here for the long term and a good regular dividend payout too for my eventual pension planning.
GLA

[chopsy] 08/1/2021 09:56

Quiet day, share price wise?

[pogue] 08/1/2021 09:56

Bobsworth
It’s all about the news flow. It will change here soon. Sit and wait.

[zeus19] 08/1/2021 09:52

Just topped up another 24899 shares but not showing

[bobsworth] 08/1/2021 09:46

Crazy times!
Watching loss making shares rise here on jam tomorrow hopes while cash generating shares like ORPH continue to be held back by the likes of Invesco selling. Why does this keep happening to an excellent company like ORPH (example: Woodford Fund) and how can Cathal avoid this happening again?
Yes I am all topped up now and want this to stop!
GLA

[chelsea101] 07/1/2021 21:14

For those unable to open link:- Open Orphan


Open Orphan (AIM:ORPH), a contract research organization (CRO), for the testing of vaccines and antivirals, made waves this October with the award of a contract with the UK Government to conduct the world’s first Covid-19 ‘challenge study’.

The study, to be conducted by the company’s hVIVO subsidiary, will see, to discover the minimum amount of the virus it takes to develop Covid-19, and thereby help calibrate the future development of the vaccine. The first stage of this project will explore the feasibility of exposing healthy volunteers to the virus: if the research is approved by regulators it will begin early next year with results expected by May. The contract, which has already commenced, could be worth some £10m to hVIVO depending upon the final number of volunteers included in the characterisation study. hVIVO also offers a full range of COVID-19 tests through its COVID Clear programme.

The contract offers the prospect of a healthy return on Open Orphan’s investment in hVIVO, which it acquired for £13m in equity in January. The company’s interim results for the six months ended 30 June 2020 stated a cash balance of £14.7m following two successful placings in January and May. An EBITDA loss of £4.1m for H1 2020 was recorded, but the company is targeting near-term profitability in light of its strong pipeline of contracted work. It should be noted Open Orphan has another major subsidiary, Venn Life Sciences, offering drug development consultancy, clinical trial design and execution. Venn’s capabilities include CMC, Non-Clinical, Clinical Development and Regulatory Affairs.

Unsurprisingly Open Orphan’s share price has gathered spectacular momentum this year, rising from less than 5p in January to nearly 25p today. Continued uncertainty regarding the UK’s emergence from the pandemic means Open Orphan’s strong run may continue for some time yet.

[hotteruk6] 07/1/2021 20:42

I am still here, holding and waiting. Chart looks like share price ready to double within 3 months to me. Ignore the daily noise.

[chelsea101] 07/1/2021 20:41

hxxps://total-market-solutions.com/2021/01/12-companies-to-follow-in-2021/

[owenski] 07/1/2021 16:59

Indeed, considering the CEO is no scientist, he's pretty much called the scenario right here from the off, there again, his intel comes from some top people in the company.

[toyin] 07/1/2021 16:24

No problem raf.

[rafboy] 07/1/2021 15:48

Thanks Toyin, appreciated.

[toyin] 07/1/2021 15:45

Start with these raf.

"Trade your way to financial freedom" (not just charts, psychology as well)
"Technical analysis of stock trends"
"Trade like a stock market wizard"

Edit: back at my desk a few more for you.

"Getting started in chart Patterns"
"Getting started in technical analysis"
"Technical analysis masterclass"

www.thepatternsite.com

[rafboy] 07/1/2021 15:27

Can anyone recommend a good charting book? It’s about time I learnt more of this dark art. Thanks.

[wassapper] 07/1/2021 14:29

Still can't buy any on IG spreadbets. Closing only. Glad I have a good amount there.

[judijudi] 07/1/2021 13:11

Might even end up Blue 🤞🤞🤞

[m5] 07/1/2021 12:53

Hope we can get a nice daily pin bar, rejection of lower prices. I see price has though touched the 8DMA and rejected it. Again, its all noise until we see where we are at 4.30.

[bearnecessities] 07/1/2021 12:15

Just managed to get 50k shares at 25.7890.